Resource Logo
Reuters New Media

Gilead 4th-quarter net profit rises 15 pct, HIV drug sales beat




 

* 4th-qtr net profit rises 15 pct to $762.5 mln

* Revenue rises 18 pct to $2.59 bln

* Forecasts 2013 product sales of $10-10.2 bln

Feb 1 (Reuters) - Gilead Sciences Inc on Monday reported a 15 percent increase in quarterly net profit as sales of its flagship HIV drugs exceeded Wall Street estimates and total revenue rose by 18 percent.

For full-year 2013, the company forecast net product sales of $10 billion to $10.2 billion.

Fourth-quarter net profit rose to $762.5 million, or 47 cents per share, from $665.1 million, or 43 cents per share, a year earlier.

Sales of HIV drug Atripla rose 6 percent to $917.5 million, which beat the $874 million expected by analysts, according to numbers published by ISI Group. Sales of HIV drug Truvada rose 12 percent to $832.7 million, surpassing analysts' estimate of $793 million.

Revenue for the quarter rose 18 percent to $2.59 billion. Analysts expected $2.43 billion, according to Thomson Reuters I/B/E/S.



 


Copyright © 2013 -Reuters New Media, Publisher. All rights reserved to Reuters .Ltd. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Information in this article was accurate in February 4, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.